Results 51 to 60 of about 23,130 (165)

Novel nanobody-161 binds tumor necrosis factor receptor 2 (TNFR2) to exert an anti-tumor effect but does not block TNFα-binding

Frontiers in Immunology
BackgroundTumor necrosis factor receptor 2 (TNFR2) is expressed on regulatory T cells (Tregs) and many cancer cells indicating its potential as a therapeutic target.
Liang Huang, Chao Kong, Chao Kong, Yuhao Hu, Michael Zhang, Shuangqi Li, Wanjing Wang, Hui Guan, Mei Ling Lim, Zhen Zhang, Wenhai Zhang, Hailiang Zheng, Xintian Yan, Xinglu Sun, Pan Lei, Shanshan Dai, Wenrong Wang, Linlin Lu, Junma Zhou, Shilong Fan, Guojun Lang   +20 more
doaj   +1 more source

biopharmaceutics

Citation: 'biopharmaceutics' in the IUPAC Compendium of Chemical Terminology, 5th ed.; International Union of Pure and Applied Chemistry; 2025. Online version 5.0.0, 2025. 10.1351/goldbook.15156 • License: The IUPAC Gold Book is licensed under Creative Commons Attribution-ShareAlike CC BY-SA 4.0 International for individual terms.
openaire   +1 more source

Immunogenicity and efficacy of an mRNA vaccine expressing a virus-like particle spike antigen against SARS-CoV-2

npj Vaccines
The COVID-19 pandemic spurred mRNA vaccine innovation, but new SARS-CoV-2 variants highlight the need for vaccines with improved potency and durability.
Jason P. Laliberte, Yingyun Cai, Tara Kenny, Yi Zhang, Kuishu Ren, Kim Rosenthal, Daniel Flores, Richard Roque, Oliver Acton, Vanessa Cadevilla Peano, Noel Janney, Vinita Puri, Sarah Siddiqui, Angela Pack, Giune Padilla, Seme Diallo, Hibret Adissu, Rakesh Choudhary, Hawley Pruitt, Yi-Han Cheng, George Thom, Michael Newton, Cheyne Kurokawa, Johnathan Guest, Phillip Swanson, Yueh-Ming Loo, Joseph R. Francica, Wade Blair, Mark Esser   +28 more
doaj   +1 more source

Biopharmaceuticals: Priority Sector Report

, 2019
The Biopharmaceuticals emerging industry is the result of an evolution of the traditional pharmaceutical industry that emerged in the late 1800s, mainly based on chemical production. The industry has incorporated the more recent emergence of biotechnology developed on living cells and molecules, stemming from key innovations in the 1970s and 1980s ...
openaire   +2 more sources

Author Correction: Benralizumab versus placebo for hypereosinophilic syndrome: a randomized, placebo-controlled phase 3 trial. [PDF]

Nat Med
Ogbogu PU, Roufosse F, Akuthota P, Kuna P, Groh M, Reiter A, Yokota A, Siddiqui SH, Mutsaers PGNJ, Li B, Khoury P, Bahadori LM, Bednarczyk A, Bouma G, Brooks LG, Ferreira J, Grindebacke H, Ho CN, Jain P, Palmer RL, Jison ML, Klion AD, NATRON study group.   +22 more
europepmc   +1 more source

Biopharmaceutics [PDF]

, 2020
openaire   +1 more source

Safety Profile of Tozorakimab (an Anti-IL-33 Monoclonal Antibody): Data from the FRONTIER Phase 2 Program. [PDF]

Biologics
Patel R, Brooks D, Gorseth E, Moate R, Hofherr A, Kell C, Luporini Saraiva G, Pandya H, Jenkins M, Psallidas I.   +9 more
europepmc   +1 more source

Phase III LUNA clinical programme: design of four randomised, double-blind, placebo-controlled studies assessing the efficacy and safety of tozorakimab in patients with symptomatic COPD and a high risk of exacerbations. [PDF]

BMJ Open Respir Res
Watz H, Sciurba FC, Bonini M, Yañez A, Bourdin A, Zheng J, De Soyza A, Janssens W, van den Berge M, Xu JF, Saraiva GL, Jenkins M, Jimenez E, Lofdahl M, Li J, Mikosz M, Kishishita N, Jackson S, Johnson S, Patel R, Fagerås M, Psallidas I.   +21 more
europepmc   +1 more source

Author Correction: Phenome-wide analysis of copy number variants in 470,727 UK Biobank genomes. [PDF]

Nature
Zou XZ, Hu F, Lou H, Burren OS, Li X, Megy K, Wheeler E, Wu Q, Atanur SS, Karpinski M, Loesch D, Fairhurst-Hunter Z, Deevi SVV, Oerton E, Wen S, Jiang X, Salvoro C, Mitchell J, Nag A, Hollis B, O'Neill A, AstraZeneca Genomics Initiative, Harrow J, MacArthur S, Wasilewski S, O'Dell S, Tian L, Smith KR, Del Angel G, Fabre M, Dhindsa RS, Wang Q, Petrovski S, Carss K.   +33 more
europepmc   +1 more source

Biopharmaceutics

Journal of Pharmacy and Pharmacology, 2006
openaire   +2 more sources